Skip to NavigationSkip to content

Roche celebrates European approval of Tecentriq combo in first-line lung cancer

Published on 06/09/19 at 12:42pm

Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

Phase 3 data submitted in support of the application showed that the Tecentriq combo “helped people live significantly longer compared with chemotherapy alone”, improving median overall survival by 12.3 months compared to 10.3 months with chemotherapy alone in the intent-to-treat population.

Additionally, the combo was also successful in reducing the risk of disease progression or death by 5.2 months, compared to 4.3 months with chemotherapy alone.

“This approval makes Tecentriq the first cancer immunotherapy available in Europe for the initial treatment of extensive-stage small cell lung cancer, marking an important step forward for patients,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “The combination of Tecentriq and chemotherapy has been shown to improve survival compared to the current standard-of-care – an advance that, until now, has been difficult to achieve due to the refractory nature of this disease.”

Roche is currently Tecenetriq in nine different Phase 3 lung cancer studies, whether as a monotherapy or as part of a combination.  

Matt Fellows

Comments

Great article Lot's of information to Read...Great Man Keep Posting and update to People..Thanks bridal boutique

Wow i can say that this is another great article as expected of this blog.Bookmarked this site.. Omni Centers

It is a great website.. The Design looks very good.. Keep working like that!. kumpulan situs judi bola terpercaya

Its a great pleasure reading your post.Its full of information I am looking for and I love to post a comment that "The content of your post is awesome" Great work. Atlanta wedding DJs

Thanks, that was a really cool read! 401k plan rules

The information you have posted is very useful. The sites you have referred was good. Thanks for sharing.. Connecticut Pest Control

I read that Post and got it fine and informative. Please share more like that... bridesmaid dresses

Thanks for sharing this useful info.. diving

I just found this blog and have high hopes for it to continue. Keep up the great work, its hard to find good ones. I have added to my favorites. Thank You. Port St Lucie Real Estate Agent

I am hoping the same best effort from you in the future as well. In fact your creative writing skills has inspired me. manhattan printing

Your website is really cool and this is a great inspiring article. Thank you so much. model planes for sale

Your music is amazing. You have some very talented artists. I wish you the best of success. okcupid review

thanks this is good blog. commercial security

I really appreciate the kind of topics you post here. Thanks for sharing us a great information that is actually helpful. Good day! voyance tel

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches